The estimated Net Worth of Carl Ashley Morris is at least $4.44 Millón dollars as of 27 January 2023. Carl Morris owns over 1,233 units of Solid Biosciences Inc stock worth over $151,305 and over the last 7 years he sold SLDB stock worth over $231,770. In addition, he makes $4,052,210 as Chief Scientific Officer at Solid Biosciences Inc.
Carl has made over 5 trades of the Solid Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,233 units of SLDB stock worth $9,235 on 27 January 2023.
The largest trade he's ever made was selling 23,398 units of Solid Biosciences Inc stock on 12 March 2021 worth over $206,838. On average, Carl trades about 4,686 units every 61 days since 2018. As of 27 January 2023 he still owns at least 20,201 units of Solid Biosciences Inc stock.
You can see the complete history of Carl Morris stock trades at the bottom of the page.
Dr. Carl Morris Ph.D. serves as Chief Scientific Officer of the Company since June 2017, and previously served as our Senior Vice President of Research and Development from September 2015 to June 2017. Prior to joining us, Dr. Morris held various leadership positions within Pfizer Inc.’s, or Pfizer’s, Rare Disease Research Unit from January 2010 to August 2015, including serving as a Senior Director, Director and Senior Principal Scientist. Prior to Pfizer, Dr. Morris held various positions within the Tissue Repair unit at Wyeth Pharmaceuticals, Inc., a pharmaceutical company acquired by Pfizer. Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit. He is also co-founder and a member of the board of directors of Breed Nutrition Inc. Dr. Morris holds a B.A. in Biology from Franklin Pierce College and a Ph.D. in Physiology from UCLA.
As the Chief Scientific Officer of Solid Biosciences Inc, the total compensation of Carl Morris at Solid Biosciences Inc is $4,052,210. There are no executives at Solid Biosciences Inc getting paid more.
Carl Morris is 50, he's been the Chief Scientific Officer of Solid Biosciences Inc since 2017. There are 10 older and 8 younger executives at Solid Biosciences Inc. The oldest executive at Solid Biosciences Inc is Stephen J. DiPalma M.B.A., 62, who is the Treasurer & Principal Accounting Officer.
Carl's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.
Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ... y Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Solid Biosciences Inc executives and other stock owners filed with the SEC include: